The global constrained peptide drugs market is anticipated to be valued at $60.1 million in 2023 and is expected to reach $10,367.2 million by 2031, witnessing a CAGR of 90.37% during the forecast period 2023-2031. The market growth in revenue is largely fueled by the promise of a novel breakthrough constrained peptide pipeline, which is no longer restricted to receptor targets. Advancements in chemical technologies, the therapeutics success of commercialized synthetic peptides in recent years, and the affordable pricing being realized by these biomolecules in a wide range of diseases are some additional factors attributing to the projected growth in the forecast period. Market Segmentation • Product: BT1718, BT5528, Zilucoplan (RA101495), Rusfertide (PTG-300), PN-943 • Peptide Type: Cyclic Peptides, Disulfide-Rich Peptides (DRPs) • Region: North America, Europe, Asia-Pacific Regional Segmentation • North America – U.S. and Can...